XENON PHARMACEUTICALS

Xenon Pharmaceuticals presents long-term azetukalner data from X-TOLE OLE study at AES 2024, showing sustained seizure reduction and consistent safety profile. 32.7% of patients treated for >36 months achieved seizure freedom for at least 12 months. Azetukalner continues to be well-tolerated, with no new safety signals identified.

Xenon Pharmaceuticals, focused on neurological disorders, advances azetukalner, its lead drug candidate for epilepsy and MDD, through late-stage trials. Key milestones include Phase III X-TOLE2 study readout in 2025 and initiation of MDD study in 2024. Analysts project blockbuster potential for azetukalner, with market estimates exceeding $1 billion for epilepsy and $700 million for MDD. Xenon's financial performance and analyst ratings remain positive, with price targets ranging from $55 to $65. The company faces risks from potential trial delays and competitive market dynamics.

DelveInsight's 'Epilepsy Pipeline Insight, 2024' report details 75+ companies developing 90+ therapies, including RLS103, CT-010, EQU 001, and others, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Novartis, Pfizer, Sanofi, and Takeda, among others.